RT Journal Article SR Electronic T1 ANP 235 JF Drug and Therapeutics Bulletin JO Drug Ther Bull FD BMJ Publishing Group Ltd SP 66 OP 68 DO 10.1136/dtb.2.17.66 VO 2 IS 17 YR 1964 UL http://dtb.bmj.com/content/2/17/66.abstract AB ANP 235, which has not yet been given an approved name, is sold in this country by Lloyd Anphar. It has been advertised in some of the medical press quite soberly but not very informatively, featuring eight ‘facts’. One of these is that the reference list now exceeds 150 publications. Though this appears to be true, the information is of no value to medical practitioners unless it is critically evaluated. The assertion that many of the papers are adequate double-blind trials is debatable. The manufacturer's list contains only favourable reports and almost all the papers are in French, Italian and German. At our request they very kindly selected ten which they themselves regard as the most impressive. We have also consulted a more extensive selection which they supplied in translation.